Acute Myeloid Leukemia Registry
AMLREGISTRY
1 other identifier
observational
250
1 country
1
Brief Summary
All acute myeloid leukemia (AML) patients diagnosed after 1 Jan 2020 will be included to this study.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Dec 2021
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
December 21, 2021
CompletedFirst Submitted
Initial submission to the registry
July 29, 2023
CompletedFirst Posted
Study publicly available on registry
August 7, 2023
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 21, 2026
ExpectedStudy Completion
Last participant's last visit for all outcomes
December 21, 2026
August 7, 2023
July 1, 2023
5 years
July 29, 2023
July 29, 2023
Conditions
Outcome Measures
Primary Outcomes (1)
Overall Survival
From diagnosis to exits by any cause
60 months
Eligibility Criteria
All AML patients diagnosed after 1 Jan 2020 will be included to this study.
You may qualify if:
- Diagnosed as AML after 1 Jan 2020
- Patients signed informed consent form
You may not qualify if:
- Patients under 18 years old
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Antalya Training and Research Hospital
Antalya, Turkey (Türkiye)
Related Publications (2)
Karakus V, Pinar IE, Iltar U, Yenihayat EM, Polat MG, Celik S, Malkan UY, Cengiz Seval G, Dogan A, Akdeniz A, Ozbalci D, Ince I, Erdem R, Mehtap O, Kirkizlar HO, Kacmaz M, Deveci B, Aykas F, Korkmaz G, Yigit Kaya S, Afacan Ozturk HB, Sevindik OG, Can F, Cekdemir D, Aslan C, Bulbul H, Karabulut ZT, Maral S, Durusoy SS, Demirkan F, Goker H, Ozkalemkas F, Keklik M, Toprak SK, Karatas AF, Atas U, Alacacioglu I; Turkish Society of Hematology-Acute Leukemias Working Group. Clinical Characteristics, Treatment Approaches, and Survival Predictors in Adult Acute Myeloid Leukemia: Interim Results from the Turkish Society of Hematology AML Registry. J Clin Med. 2025 Oct 18;14(20):7367. doi: 10.3390/jcm14207367.
PMID: 41156238DERIVEDPinar IE, Celik S, Polat MG, Karatas AF, Dogan A, Iltar U, Cengiz Seval G, Malkan UY, Ince I, Yenihayat EM, Akdeniz A, Kacmaz M, Erdem R, Afacan Ozturk HB, Kirkizlar HO, Korkmaz G, Aykas F, Mehtap O, Deveci B, Sevindik OG, Can F, Ozbalci D, Bulbul H, Durusoy SS, Atas U, Keklik M, Toprak SK, Goker H, Demirkan F, Ozkalemkas F, Alacacioglu I, Karakus V; Turkish Society of Hematology-Acute Leukemias Working Group. Comprehensive analysis of FLT3-mutated patients with acute myeloid leukemia with updated 2022 European LeukemiaNet recommendations: insights from the Turkish AML registry project. BMC Cancer. 2025 Oct 10;25(1):1546. doi: 10.1186/s12885-025-14987-z.
PMID: 41073967DERIVED
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
Ilker Kurkcu
Sentez Cro
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Target Duration
- 24 Months
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
July 29, 2023
First Posted
August 7, 2023
Study Start
December 21, 2021
Primary Completion (Estimated)
December 21, 2026
Study Completion (Estimated)
December 21, 2026
Last Updated
August 7, 2023
Record last verified: 2023-07
Data Sharing
- IPD Sharing
- Will not share